Strategies to overcome accelerated repopulation and hypoxia - What have we learned from clinical trials?

Seminars in Oncology

Volumn 31, Issue 6, 2004, Pages 802-808

  Corry, June ^a   Rischin, Danny ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b A'Beckett St Melbourne A   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; 2 NITROIMIDAZOLE; 2 NITROIMIDAZOLE DERIVATIVE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CARBOGEN; CARBOPLATIN; CISPLATIN; COPPER DERIVATIVE; COPPER DIACETYLBIS(N4 METHYLTHIOSEMICARBAZONE); CYTOTOXIN; FLUOROAZOMYCIN ARABINOSIDE; FLUOROURACIL; NICOTINAMIDE; NIMORAZOLE; NITROIMIDAZOLE DERIVATIVE; PIMONIDAZOLE; RADIOSENSITIZING AGENT; TIRAPAZAMINE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CLINICAL TRIAL; FEBRILE NEUTROPENIA; FRACTIONATION; HEAD AND NECK CARCINOMA; HUMAN; HYPERBARIC OXYGEN; HYPOXIA; HYPOXIC CELL; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SQUAMOUS CELL CARCINOMA; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR DIFFERENTIATION;

EID: 10044237958     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.09.005     Document Type: Article

References (49)

1. L.J. Peters, G.H. Fletcher Causes of failure of radiotherapy in head and neck cancer Radiother Oncol 1 1983 53 63
2. A.F. Hermens, G.W. Barendsen Changes of cell proliferation characteristics in a rat rhabdomyosarcoma before and after x-irradiation Eur J Cancer 5 1969 173 189
3. H.R. Withers, J.M. Taylor, B. Maciejewski The hazard of accelerated tumor clonogen repopulation during radiotherapy Acta Oncol 27 1988 131 146
4. J.C. Horiot, P. Bontemps, W. van den Bogaert Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers Results of the EORTC 22851 randomized trial Radiother Oncol 44 1997 111 121
5. S. Dische, M. Saunders, A. Barrett A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer Radiother Oncol 44 1997 123 136
6. S.M. Jackson, L.M. Weir, J.H. Hay A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer Radiother Oncol 43 1997 39 46
7. M.G. Poulsen, J.W. Denham, L.J. Peters A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck A Trans-Tasman Radiation Oncology Group Study Radiother Oncol 60 2000 113 122
8. K. Skladowski, B. Maciejewski, M. Golen Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer--Report on 3-year tumour control and normal tissue toxicity Radiother Oncol 55 2000 101 110
9. J.L.M. Bourhis, J. Torochaux Very accelerated versus conventional radiotherapy in HNSCC Results of the GORTEC 94-02 randomized trial Int J Radiat Oncol Biol Phys 48 suppl 2000 S111 (abstr)
10. J. Overgaard, H.S. Hansen, L. Specht Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck DAHANCA 6 and 7 randomised controlled trial Lancet 362 2003 933 940
11. K.K. Fu, T.F. Pajak, A. Trotti A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas First report of RTOG 9003 Int J Radiat Oncol Biol Phys 48 2000 7 16
12. O. Hansen, J. Overgaard, H.S. Hansen Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma Dependency on tumor differentiation Radiother Oncol 43 1997 47 51
13. R.K. Schmidt-Ullrich, R.B. Mikkelsen, P. Dent Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation Oncogene 15 1997 1191 1197
14. J. Eriksen, T. Steiniche, J. Alsner The prognostic significance of EGFr is related to tumor cell differentiation and the fractionation of radiotherapy in squamous cell carcinoma of the head and neck Proceedings of the 2nd ESTRO Workshop in Biology in Radiation Oncology 2003 Berg en Dal/Nijmegen Netherlands June 1-3
15. G. Calais, M. Alfonsi, E. Bardet Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma J Natl Cancer Inst 91 1999 2081 2086
16. D.M. Brizel, M.E. Albers, S.R. Fisher Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer N Engl J Med 338 1998 1798 1804
17. B. Jeremic, Y. Shibamoto, B. Stanisavljevic Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck A prospective randomized trial Radiother Oncol 43 1997 29 37
18. T.G. Wendt, G.G. Grabenbauer, C.M. Rodel Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer A randomized multicenter study J Clin Oncol 16 1998 1318 1324
19. D.J. Adelstein, Y. Li, G.L. Adams An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer J Clin Oncol 21 2003 92 98
20. S. Staar, V. Rudat, H. Stuetzer Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-- Results of a multicentric randomized German trial in advanced head-and-neck cancer Int J Radiat Oncol Biol Phys 50 2001 1161 1171
21. J. Overgaard, M.R. Horsman Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers Semin Radiat Oncol 6 1996 10 21
22. M. Nordsmark, M. Overgaard, J. Overgaard Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck Radiother Oncol 41 1996 31 39
23. D.M. Brizel, G.S. Sibley, L.R. Prosnitz Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck Int J Radiat Oncol Biol Phys 38 1997 285 289
24. P. Stadler, A. Becker, H.J. Feldmann Influence of the hypoxic subvolume on the survival of patients with head and neck cancer Int J Radiat Oncol Biol Phys 44 1999 749 754
25. 2 histography in patients with advanced head and neck cancer Strahlenther Onkol 177 2001 462 468
26. B. Vanselow, M.J. Eble, V. Rudat Oxygenation of advanced head and neck cancer Prognostic marker for the response to primary radiochemotherapy Otolaryngol Head Neck Surg 122 2000 856 862
27. R.A. Gatenby, H.B. Kessler, J.S. Rosenblum Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy Int J Radiat Oncol Biol Phys 14 1988 831 838
28. P.L. Olive, J.P. Banath, C. Aquino-Parsons Measuring hypoxia in solid tumours--Is there a gold standard? Acta Oncol 40 2001 917 923
29. M. Nordsmark, J. Loncaster, C. Aquino-Parsons Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas Radiother Oncol 67 2003 35 44
30. M. Nozue, I. Lee, F. Yuan Interlaboratory variation in oxygen tension measurement by Eppendorf "histograph" and comparison with hypoxic marker J Surg Oncol 66 1997 30 38
31. J.H. Kaanders, K.I. Wijffels, H.A. Marres Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer Cancer Res 62 2002 7066 7074
32. S.M. Evans, S. Hahn, D.R. Pook Detection of hypoxia in human squamous cell carcinoma by EF5 binding Cancer Res 60 2000 2018 2024
33. 18F] fluoromisonidazole A pretherapy study of 37 patients Int J Radiat Oncol Biol Phys 36 1996 417 428
34. D. Rischin, L. Peters, R. Hicks Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer J Clin Oncol 19 2001 535 542
35. 18F]-EF5, a marker for PET detection of hypoxia Synthesis of precursor and a new fluorination procedure Appl Radiat Isot 54 2001 73 80
36. 18F] fluoromisonidazole (18FMISO) A comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors Nucl Med Biol 30 2003 317 326
37. 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer Ann Nucl Med 14 2000 323 328
38. D. Rischin, L. Peters, J. Smith Preliminary results of TROG 98.02--A randomised phase II study of 5-fluorouracil, cisplatin and radiation versus tirapazamine, cisplatin and radiation for advanced squamous cell carcinoma of the head and neck Proc Am Soc Clin Oncol 22 2003 495 (abstr 1991)
39. B.G. Haffty, R. Hurley, L.J. Peters Radiation therapy with hyperbaric oxygen at 4 atmospheres pressure in the management of squamous cell carcinoma of the head and neck results of a randomized clinical trial Cancer J Sci Am 5 1999 341 347
40. J.M. Henk, P.B. Kunkler, C.W. Smith Radiotherapy and hyperbaric oxygen in head and neck cancer. Final report of first controlled clinical trial Lancet 2 1977 101 103
41. J. Overgaard Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors Oncol Res 6 1994 509 518
42. J. Overgaard, H.S. Hansen, M. Overgaard A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85 Radiother Oncol 46 1998 135 146
43. J. Bernier, J. Denekamp, A. Rojas ARCON: Accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the European Organization for Research and Treatment of Cancer (EORTC) Radiother Oncol 55 2000 111 119
44. J.H. Kaanders, L.A. Pop, H.A. Marres ARCON experience in 215 patients with advanced head-and-neck cancer Int J Radiat Oncol Biol Phys 52 2002 769 778
45. J.M. Brown SR 4233 (tirapazamine) A new anticancer drug exploiting hypoxia in solid tumours Br J Cancer 67 1993 1163 1170
46. J.M. Brown, M.J. Lemmon Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors Cancer Res 50 1990 7745 7749
47. M.J. Dorie, J.M. Brown Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin Cancer Res 53 1993 4633 4636
48. C.J. Koch Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin Cancer Res 53 1993 3992 3997
49. A. Hliniak, B. Gwiazdowska, Z. Szutkowski A multicentre randomized/controlled trial of a conventional versus modestly accelerated radiotherapy in the laryngeal cancer Influence of a 1 week shortening overall time Radiother Oncol 62 2002 1 10